Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Vaccine wars ignite in California as lawmakers seek stronger laws

California is poised to become the front line of America's vaccination wars. State lawmakers are drafting the toughest covid-19 vaccine legislation in the country, backed by a new pro-vaccine lobbying force promising to counter anti-vaccine activists who have threatened government officials and shut down public meetings across the state.

24 Jan 2022

Researchers are in the race to beat Omicron

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and his team worked around the clock to post four coronavirus papers on the preprint server bioRxiv.

24 Jan 2022

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

A recent study published in the journal Science brings a detailed chemical and molecular perspective on the improved evasion of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the retention of strong interactions with the receptor as two principal factors underneath the notorious transmissibility of the SARS-CoV-2 Omicron variant.

23 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Researchers design neural network to predict severity of COVID-19 variants

In a new study, researchers predict the risk of infection with severe coronavirus disease 2019 from the sequence of the spike protein.

21 Jan 2022

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

In a new study, researchers assessed the efficacy of the FDA-approved therapeutic mAbs, as well as to small-molecule antiviral agents against the SARS-CoV-2 Omicron variant in Syrian hamsters.

21 Jan 2022

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

A new study showed that the SARS-CoV-2 Omicron spike binds to its receptor with enhanced affinity and yet evades vaccine-elicited neutralizing antibodies and that a booster mRNA vaccine broadened the neutralization of Omicron.

21 Jan 2022

Patient, beware: Some states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

21 Jan 2022

A novel assay for the rapid detection of SARS-CoV-2 variants

A new study discusses a new assay method designed by researchers to identify SARS-CoV-2 variants.

20 Jan 2022

Variants of SARS-CoV-2 and preventive strategies

A recent review article published in the journal Advanced Science reviewed the features of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants. Using a physical and materials science perspective, the review also summarizes the most significant variants of SARS-CoV-2 encountered to date as well as possible preventive strategies.

19 Jan 2022

Novel antibody that targets the N-terminal domain of SARS-CoV-2 identified

A new study discusses the targeted discovery of NTD-reactive antibodies from an individual who had recovered from SARS-CoV-2 infection.

19 Jan 2022

Evidence that monoclonal antibodies can reduce COVID-19 (Delta) mortality

Researchers prevent evidence on the efficacy of neutralizing monoclonal antibodies in treating COVID-19.

17 Jan 2022

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

A team of researchers assessed the immune response after administering a SARS-COV-2 vaccine in immuno-compromised subjects who are potentially at an increased risk to experience severe COVID-19 and inadequate response to SARS-CoV2 vaccination.

17 Jan 2022

WHO's recommendation provides two new options for treating COVID-19

WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.

16 Jan 2022

Rapid antigen test for SARS-CoV-2 proves to be highly accurate for pediatric populations

In a large prospective study of just over 1,000 patients ages 17 and younger who were seen at the Baltimore Convention Center Field Hospital (BCCFH) testing site during a seven-month period last year, researchers from Johns Hopkins Medicine and collaborating institutions report that a rapid antigen test for SARS-CoV-2 — the virus that causes COVID-19 — proved highly accurate when compared to the established standard virus detection method: the polymerase chain reaction (PCR).

16 Jan 2022

A clinical tool for monoclonal antibody allocation to treat COVID-19

In this research paper, a group of Mayo Clinic researchers discusses how data from MATRx's clinical prioritizing algorithms can be used to address anti-spike monoclonal antibody allocation during times of scarcity.

13 Jan 2022

Providing recombinant antibody services and more within Europe

In this interview, News-Medical talks to Dr. Zhang Linlin, Technical Specialist at Sino Biological Europe, about their recombinant antibody services and more that they can provide within Europe. Image credit: Corona Borealis Studio/Shutterstock.com

From Sino Biological Inc. 11 Jan 2022

Optimal monoclonal antibodies against SARS-CoV-2 variants

Researchers screen different monoclonal antibodies to identify an optimal mAb with higher binding affinity to the receptor-binding domain of SARS-CoV-2.

10 Jan 2022

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

Scientists discover antibody that inhibits a broad range of sarbecoviruses

Scientists have discovered an antibody that may lead to more effective treatments against a wide range of sarbecoviruses, the family of viruses that includes the coronavirus SARS-CoV-2 and their variants.

7 Jan 2022